Chlamydia pneumoniae and cardiovascular disease. by Campbell, L. A. et al.
571 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
Synopses
Chlamydia pneumoniae, a common cause of
human respiratory disease, was first isolated
from the conjunctiva of a child in Taiwan in 1965
and was established as a major respiratory
pathogen in 1983 when it was isolated from the
throat of a college student at the University of
Washington.  C. pneumoniae causes approxi-
mately 10% of community-acquired pneumonia
and 5% of pharyngitis, bronchitis, and sinusitis
(1). The clinical symptoms of C. pneumoniae
pulmonary infections are similar to those caused
by other respiratory pathogens, except for a few
distinguishing features (1). Subacute onset and
pharyngitis are common. Often a biphasic
pattern is observed, with pharyngitis resolving
before bronchitis or pneumonia develops. Cough
is very common and prolonged. Although
pneumonia is often relatively mild, recovery is
slow, even with antibiotic therapy; and cough
and malaise may persist for many weeks.
Considerable knowledge of the epidemiology
of C. pneumoniae infection has been derived from
serologic studies using the C. pneumoniaespecific
microimmunofluorescence test. C. pneumoniae
infection is ubiquitous. Virtually everyone is
infected at some point in life, and reinfection occurs
commonly. Antibodies against C. pneumoniae are
rare in children under the age of 5, except in
developing and tropical countries. Antibody
prevalence increases rapidly at ages 5 to 14,
reaches 50% at the age of 20, and continues to
increase slowly to 70% to 80% at ages 60 to 70 (1).
C. pneumoniae has been associated with
other acute and chronic respiratory diseases
(e.g., otitis media, chronic obstructive pulmo-
nary disease, pulmonary exacerbation of cystic
fibrosis, and asthma) as well as other clinical
syndromes (e.g., erythema nodosum, Reiter
syndrome, and sarcoidosis [1]). These associa-
tions are determined by seroepidemiologic
observations, case reports, isolation or direct
detection of the organism in specimens,
successful response to antichlamydial antibiot-
ics, or a combination of these methods.
The expanding spectrum of C. pneumoniae
infection has been extended to atherosclerosis and
related clinical manifestations such as coronary
heart disease, carotid artery stenosis, aortic
aneurysm, claudication (occlusion of the arteries
of the lower extremities), and stroke. This overview
summarizes the studies associating C. pneumoniae
infection with atherosclerosis and discusses
preliminary in vitro and in vivo studies
suggesting the plausibility of a causative role.
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Chlamydia pneumoniae is a ubiquitous pathogen that causes acute respiratory
disease. The spectrum of C. pneumoniae infection has been extended to
atherosclerosis and its clinical manifestations. Seroepidemiologic studies have
associated C. pneumoniae antibody with coronary artery disease, myocardial
infarction, carotid artery disease, and cerebrovascular disease. The association of
C. pneumoniae with atherosclerosis is corroborated by the presence of the organism
in atherosclerotic lesions throughout the arterial tree and the near absence of the
organism in healthy arterial tissue. C. pneumoniae has also been isolated from
coronary and carotid atheromatous plaques. To determine whether chronic infection
plays a role in initiation or progression of disease, intervention studies in humans have
been initiated, and animal models of C. pneumoniae infection have been developed.
This review summarizes the evidence for the association and potential role of
C. pneumoniae in cardiovascular disease.572 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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Is C. Pneumoniae Present in
Atherosclerotic Tissues?
Patients with coronary artery disease are
significantly more likely than healthy persons to
have serologic evidence of past infection with
C. pneumoniae (2,3). Immune complexes
containing  C. pneumoniae lipopolysaccharide
have also been associated with 42- and 98-kDa
C. pneumoniae species-specific antigens (4).
These associations have been confirmed and
extended to carotid artery disease and cere-
brovascular disease (5,6). Although the high
prevalence of C. pneumoniae antibodies in the
population leaves a very narrow window for
demonstrating statistically significant differ-
ences between cases and controls,
seroepidemiologic studies have shown a consis-
tent association. C. pneumoniae antibodies have
been associated with coronary heart disease (16
studies) and cerebrovascular disease (2 studies)
in 17 of 18 published studies; most had an odds
ratio of 2.0 or greater (6). Most were statistically
significant, and the risk is independent of other
atherosclerosis risk factors (i.e., hypercholester-
olemia, cigarette smoking, hypertension, diabe-
tes, and family history). Studies of 2,700 patients
and 5,000 controls have demonstrated a serologic
association of C. pneumoniae antibody and
cardiovascular disease (6).
Compelling evidence of the association
between  C. pneumoniae and atherosclerosis
has been obtained by polymerase chain
reaction (PCR), immunocytochemical (ICC)
staining, and electron microscopy, which have
detected  C. pneumoniae in atherosclerotic
lesions (Table). Structures found within coro-
nary atheromas were remarkably similar to the
pear-shaped elementary body morphologic charac-
teristics described for C. pneumoniae (Figure 1)
(25). By ICC staining using a C. pneumoniae
specific monoclonal antibody (Mab), C. pneumoniae
was demonstrated within the atherosclerotic
lesion in 5 of 7 tissues. By PCR or ICC stain, the
organism was detected in 20 of 36 coronary
artery tissues from autopsy (7). At the University
of Washington, the organism has been detected
in coronary, carotid, aortic, femoral, and
popliteal atheromas in both early lesions and
fibrolipid plaques (7-10,15,18,22,26,27). In all
studies using ICC stain, control tissues were
stained with control antibody to rule out
background staining (Figure 2). The organism
was found in tissues of male and female study
participants of different ages and ethnic groups.
Other investigators have confirmed these
findings and have also found the organism in
atherosclerotic lesions in iliac arteries and
tissues from abdominal aortic aneurysms and
Table. Studies of Chlamydia pneumoniae in atherosclerotic tissue
Atherosclerotic
Source of specimens tissuea
(reference) Artery Type of specimen (% positive)
South Africa (7) Coronary Autopsy 20/36 (56)
PDAYb study (8) Coronary Autopsy 8/18 (44)
Univ. Washington (9) Coronary Atherectomy 20/38 (53)
Alaskan Natives (10) Coronary Autopsy 23/59 (39)
Louisville, Kentucky (11) Coronary Vascular surgery 7/12 (58)
Japan (12) Coronary Atherectomy 20/29 (69)
Salt Lake City, Utah (13) Coronary Atherectomy 71/90 (79)
India (14) Coronary Coronary artery bypass 4/40 (10)
California & Univ. Washington (15) Carotid Endarterectomy 37/61 (61)
Germany (16) Carotid Endarterectomy 7/50 (14)
Canada (17 ) Carotid Endarerectomy 54/76 (71)
Univ. Washington (18) Aorta Autopsy 7/21 (33)
Finland (19) Aorta Vascular surgery 12/12 (100)
Italy (20) Aorta Vascular surgery 26/51 (51)
United Kingdom (21) Aorta, femoral, iliac Vascular surgery 15/33  (45)
California (22) Popliteal femoral Vascular bypass 10/23 (43)
Finland (23) Aortic valve Autopsy 25/46 (54)
Sweden (24) Aortic Valve Surgery 19/39 (49)
aNumber positive by immunocytochemical staining and/or polymerase chain reaction over number tested.
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aortic valve stenosis (11-14,16,17,19-21,23,24,28).
The organism has been found in atherosclerotic
lesions in 257 (52%) of 497 tissue specimens (6).
In contrast, the organism has been found in only
5% of tissues that appear normal. Remarkably,
the detection in diseased arterial tissue
compared to normal arterial tissue represents an
odds ratio of 10 [95% Confidence Interval (CI) 5-
22]. In our studies the organism was not found in
cardiovascular tissue that appeared histologi-
cally normal (5).
C. pneumoniae has been difficult to isolate
from atheromatous tissues, not surprising as
isolation from infected tissues in chronic
chlamydial infection or after repeated experi-
mental inoculation of animal models is rare.
However, the organism is often demonstrated by
DNA and antigen detection methods, and a
chronic inflammatory response persists. The
immunologic characteristics of atherosclerosis
are similar to the inflammatory response
resulting from chronic infection. In two recent
cases, C. pneumoniae has been isolated from
atheromatous plaques (11,15). The first isolate
was obtained during a multicenter study that
examined coronary arteries of patients (with or
without coronary artery disease) undergoing
heart transplants. The organism was found in
the coronary artery of 7 of 10 patients with
atherosclerosis; it was not found in two patients
without evidence of coronary atherosclerosis.
C. pneumoniae was isolated from the atheroscle-
rotic lesion of one patient with severe coronary
artery disease (11).
The second isolate was from carotid
atheroma obtained in a study of patients
undergoing carotid endarterectomy in Seattle.
C. pneumoniae was detected in 11 of 16
specimens and was cultured from a patient
undergoing elective carotid endarterectomy (15).
In addition to C. pneumoniae, other
infectious agents including herpes simplex virus
(HSV), cytomegalovirus (CMV), and Helicobacter
pylori have been associated with cardiovascular
disease. Only a few studies have concurrently
investigated the presence of C. pneumoniae and
these infectious agents within lesions. In a study
of risk factors for atherosclerosis in young
persons, 6 of 7 samples with atheromas and 2 of
11 with intimal thickening were positive for
C. pneumoniae; all 31 unaffected tissues were
negative (8). Two specimens from atheromas and
two from normal tissues were positive for CMV.
Only one coronary atheroma was positive for
both CMV and C. pneumoniae. In a study
investigating the presence of C. pneumoniae,
CMV, and HSV in atherosclerosis of the carotid
artery, C. pneumoniae was also detected more
Figure 1. Ultrastructural evidence of Chlamydia
pneumoniae  in coronary atheroma. This transmission
electron micrograph demonstrates the presence of
endosomes containing C. pneumoniae pear-shaped
elementary bodies within a foam cell in tissue from
coronary artery atheroma. Arrows in inset point to
the elementary bodies. Bar=0.5 µm. (Reprinted from
Journal of Infectious Diseases (8) with permission
from the publisher, University of Chicago Press).
Figure 2. Immunocytochemical staining demonstrat-
ing Chlamydia pneumoniae in fibrolipid plaque from
coronary artery atheroma. Panel A illustrates
positive staining of foam cells in the plaque with the
C. pneumoniaespecific monoclonal antibody TT-401.
Panel B shows negative staining of the adjacent
section using normal ascites fluid as the control.574 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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frequently (71%) than CMV and HSV (35% and
10%, respectively). Infection with two or three of
these agents occurred in 23.7 and 7.9%,
respectively, and C. pneumoniae and CMV were
independently associated with an increased risk
for thrombosis (17). In a study addressing the
presence of C. pneumoniae or H. pylori or both in
aortic aneurysm, C. pneumoniae was found in 26
of 51 patients with plaques (20). Despite the fact
that 47 of 51 patients were seropositive for H.
pylori, this agent was not detected in any
atherosclerotic plaques (20). Thus, although
C. pneumoniae and HSV or CMV may be found in
the same lesion, C. pneumoniae has been more
frequently found as the only infectious agent.
Does C. pneumoniae Play a Role in
Atherogenesis?
Despite solid evidence that C. pneumoniae
exists in atherosclerotic lesions, evidence that
the presence of the organism is related to disease
pathogenesis is circumstantial. Three possibili-
ties can be examined. The organism 1) persists in
vascular cells but does not contribute to
pathologic abnormality, 2) causes the initial
injury and induces the atherosclerotic process, or
3) accelerates the severity or progression of the
disease. If the organism is involved, its role must
fit within the context of events in atherogenesis.
The early events in lesion development include
endothelial injury or activation resulting in
monocyte/macrophage adherence to the endot-
helium, migration to the subendothelium,
uptake of oxidized low-density lipoproteins
transforming them into foam cells, and release of
cytokines. These cytokines upregulate endothe-
lial cell adhesion molecules leading to increased
leukocyte adhesion. Platelet aggregation at the
site of endothelial damage results in the release
of platelet-derived growth factor, which stimu-
lates smooth muscle cell proliferation. Dediffer-
entiated smooth muscle cells secrete collagen,
elastin, and proteoglycans leading to the
formation of fibrous tissue. The mature
fibrolipid plaque consists of a lipid/cholesterol-
rich core surrounded by a fibrous cap composed
of matrix elements (29).
Human Tissue Studies
To investigate the hypothesis that C.
pneumoniae  is an innocent bystander, one
study explored how frequently the organism was
found in tissues from different anatomic sites.
Multiple tissues, including coronary artery,
lung, liver, spleen, and bone marrow, were
obtained at autopsy from 38 patients, half of
whom had cardiovascular disease recognized
before death. Twenty-one of the patients had
C. pneumoniae in one or more tissues. Eighteen
had the organism in cardiovascular tissue (11 in
cardiovascular tissue only) and seven in both
cardiovascular and noncardiovascular tissue. Of
the remaining three C. pneumoniaepositive
patients, two had the organism only in lung
tissue and one only in the spleen. While this
study shows that C. pneumoniae could be
detected in noncardiovascular tissue, it also
shows the organism is much more frequently
found in cardiovascular tissue (27).
Another possible explanation for the fre-
quent presence of C. pneumoniae in atheroma is
that infected lung macrophages disseminate to
any granulomatous tissue. Of 33 surgical or
autopsy specimens of granuloma from patients
with tuberculosis, leprosy, coccidioidomycosis,
Crohn disease, Wegner disease, rheumatoid
nodule, giant cell tumor, or sarcoidosis, three
contained C. pneumoniae, all sarcoid skin
granulomas (27). Sarcoidosis is a disease of
unknown etiology for which a serologic association
with C. pneumoniae has been reported (30).
These studies suggest that C. pneumoniae
infected cells are found preferentially within
atheromas.
In Vitro Studies
Consistent with observations in animal
models and humans, in vitro studies have
demonstrated that vascular cells are susceptible
to  C. pneumoniae infection and that C.
pneumoniae produces productive infection in
human macrophages, endothelial cells, and
artery smooth muscle cells (31,32), key cellular
components in atherosclerosis. In vitro studies
have also measured whether infection leads to
the production of immunomodulators. The
primary host cells are the epithelial cells that
line the trachea and nasopharynx. The first
in vitro study addressing a potential role of
C. pneumoniae in atherogenesis found that
exposure of human monocyte-derived macroph-
ages to C. pneumoniae followed by the addition of
low-density lipoprotein resulted in foam cell
formation and the accumulation of cholesteryl
esters (33). Foam cell formation is an early
event in the atherosclerotic process.575 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
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Ultrastructural studies have demonstrated
C. pneumoniae in ciliated bronchial cells in mice,
in lung macrophages in mice and rabbits, and in
human foam cells (which are macrophages) and
smooth muscle cells that take up lipids (7,34,35);
by double ICC staining with chlamydia-specific
and cell-specific MAbs, C. pneumoniae was found
in both smooth muscle cells and macrophages
within aortic atheroma lesions (18). Similarly, in
specimens removed from patients with symp-
tomatic coronary artery disease, C. pneumoniae
was found within macrophages in atherectomy
tissue  was also found in tissue removed at
atherectomy,  C. pneumoniae bacteremia, as
determined by PCR positivity of buffy coat
specimens, was found in 13% of patients with
symptomatic coronary atherosclerosis; control
specimens were negative (13,53). In mouse
models of C. pneumoniae infection, C. pneumoniae
was detected by culture and PCR in peripheral
blood mononuclear cells but not in plasma after
intranasal inoculation (36).
The ability of C. pneumoniae infection to
induce production of proinflammatory and
procoagulant activities was investigated to
determine its putative role in eliciting immune
responses consistent with atherosclerotic pro-
cesses.  C. pneumoniae infection of human
vascular endothelial cells results in production of
tissue factor, increased levels of monocyte
chemotactic protein-1, and increased platelet
adhesion to infected cells (37,38). Infection of
endothelial cells also results in expression of
adhesion molecules, including E-selectin, inter-
cellular adhesion molecule-1, and vascular
adhesion molecule-1, which are important in
leukocyte adhesion (38,39). Lastly, infection of
macrophages results in the production of
proinflammatory cytokines, tumor necrosis
factor alpha, interleukin-1 beta, interleukin-6,
and interleukin-8 as well as in expression of
CD14 molecules (38,40).
Animal Models
Although studies support a potential role for
C. pneumoniae in atherogenesis, etiology can be
established only through animal models or
intervention studies. Rabbits and mice are
susceptible to C. pneumoniae infection and
provide well-defined models of atherosclerosis.
Respiratory disease in both species is character-
ized by multifocal interstitial pneumonia. The
disease is more severe and longer lasting in mice,
and organisms are reisolated more readily from
the lungs and aorta.
Rabbit models have been used to determine
whether  C. pneumoniae respiratory infection
leads to vessel wall infection and inflammatory
changes characteristic of atherosclerosis. In one
study, New Zealand White rabbits received a single
nasopharyngeal inoculation of C. pneumoniae at 1
month of age. Two of ten rabbits demonstrated
atherosclerotic changes. The changes were
observed 7 and 14 days postinoculation. One
rabbit had an accumulation of foam cells in the
aortic arch (characteristic of an early lesion) and
focal perioaortitis in the abdominal aorta (41). A
second rabbit demonstrated spindle cell prolif-
eration of smooth muscles cells in the aorta. Both
rabbits had bronchiolitis and pneumonitis (41). In
another study, atherosclerotic-li ke changes were
found in the aortas of six of nine New Zealand
White rabbits 2 to 4 weeks after they received two
inoculations of C. pneumoniae (42). In both
studies, rabbits were fed normal diets, and
atherosclerotic-like changes were not observed
in any of the controls.
We used two mouse models, C57BL/6J and
apolipoprotein E (apoE)-knockout, to test the
hypothesis that following upper respiratory tract
infection, lung macrophages are infected,
disseminate to the aorta, and contribute to
atherogenesis. C57BL/6J mice, the background
strain of apoE-knockout mice, get atherosclero-
sis only if fed a diet high in fat and cholesterol.
In contrast, apoE-knockout mice get athero-
sclerotic lesions, with some characteristics of
human disease, spontaneously on a regular
chow diet in a time- and age-dependent
manner. Using C57Bl/6J mice, we demon-
strated that after intranasal or intraperitoneal
infection,  C. pneumoniae infects alveolar and
peritoneal macrophages, respectively (36). Addi-
tionally, the organism was found in blood
monocytes and not in plasma cells, which
indicates that a cell-associated bacteremia
followed acute infection. Passive transfer by
intraperitoneal inoculation of alveolar or
peritoneal macrophages obtained from mice
inoculated intranasally or intraperitoneally
with C. pneumoniae resulted in dissemination
of infection to the lung, thymus, spleen, and
abdominal lymph nodes (36).
To determine whether infection dissemi-
nates to the aorta and is found within
atherosclerotic lesions as in human disease,576 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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apoE-knockout mice received single or multiple
intranasal inoculations. C. pneumoniae was
detected for up to 20 weeks postinfection in the
aorta and within the lesion in apparent foam
cells by ICC staining (43). When the aorta was
positive, the percentage of C. pneumoniae
positive mice was 33% to 100%. Controls
remained negative for C. pneumoniae (43). In
contrast, 1 (0.8%) of 12 animals of the
background strain (C57BL6/J mice) fed a
nonatherogenic diet contained the organism in
the aorta for up to (but not later than) 2 weeks
postinfection. Like studies of human granulo-
matous tissues and tissues from different
anatomic sites (27,43), these studies suggest
that the organism has a tropism to atheroscle-
rotic lesions.
Computer-assisted morphometric analy-
sis of lesion size has been used to determine
if  C. pneumoniae infection alters disease
progression. Comparisons of 10 infected and 10
uninfected mice at different times following
three intranasal inoculations of C. pneumoniae
suggest that infection significantly augments
the progression of lesion size (44). Thus, early
studies in rabbit and mouse models indicate
that  C. pneumoniae infection can induce
inflammatory changes similar to those of
atherogenesis and augment the progression of
the atherosclerotic lesion.
Persistent Infection
Although C. pneumoniae antigen and DNA
are often found in atheromas, isolation is rare.
Similarly, in the mouse model of C. pneumoniae
infection, lungs remain PCR positive and
pathologic lesions persist after the organism can
no longer be cultured. In the apoE model, the
organism can be cultured from the lung and
aorta in a few mice for up to 3 weeks postinfection
but is detected by PCR and ICC up to 20 weeks
postinfection at both sites. Does PCR positivity in
the absence of culture positivity reflect
persistent infection or undegraded DNA? Two
lines of evidence strongly support the presence of
viable organisms. Two independent studies
using two different strains of mice have
demonstrated that lung infection could be
reactivated by treatment with cortisone (45,46),
specifically after intranasal inoculation, when
the organism could no longer be cultured from
lungs. Animals were treated with cortisone or
saline. With saline tratment, C. pneumoniae was
not cultured, although animals were frequently
PCR positive. In contrast, with cortisone
treatment, reactivated infection was demon-
strated by culture in 46% and 60% of infected
mice. The second line of evidence came from mice
acutely infected intranasally with live or UV-
inactivated organisms; alveolar macrophages
were isolated at various times postinfection.
When live organisms were used, the organism
could be cultured and detected by PCR up to 7
days postinfection. In contrast, when mice were
inoculated with UV-inactivated organisms, the
organism could only be detected by PCR
immediately after inoculation in isolated
macrophages (36). These experiments demon-
strated that DNA from dead organisms is rapidly
degraded, whereas live organisms survive
within macrophages.
Drug efficacy studies of chlamydia in animal
models or humans must be interpreted with
caution because chlamydial infections can
persist after antibiotic therapy. The efficacy of
two antibiotic therapies was investigated in the
mouse model of pneumonitis. After infection,
mice were treated with a single dose of
doxycycline each day for 3 days or with a single
dose of azithromycin. After either treatment,
when the organism could no longer be cultured,
the infection appeared to be cleared. However,
C. pneumoniae DNA could be detected by PCR
isolation in 25% or 77% of mouse lungs,
depending on the infecting dose. No differences
were observed in the lungs of treated and
untreated mice (47). These results suggest that
the organism can persist after single-dose
treatment regimens and that prolonged treat-
ment may be needed.
Intervention Studies
Animal Models
Animal models of C. pneumoniae infection
and atherosclerosis further define a causative
role by determining whether intervention with
antimicrobial agents can alter disease progres-
sion and by identifying successful treatment
regimens. New Zealand White rabbits were fed a
diet with 0.25% cholesterol and were inoculated
intranasally three times with C. pneumoniae
(48). Infected rabbits and controls were treated
for 7 weeks with azithromycin. Three months577 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
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after the final inoculation, the maximal intimal
thickness (MIT) of the thoracic aortas increased
in infected rabbits but not in controls.  The MIT
of azithromycin-treated rabbits was less than
that of untreated infected rabbits and similar to
that of controls. However, the organism was
detected by immunofluorescence in the aorta of
treated rabbits as frequently as it was detected in
the aorta of untreated rabbits (48).
Human Studies
Three small pilot studies on the potential use
of antibiotics against C. pneumoniae have
yielded promising results. The first intervention
study focused on male patients at least 6 months
after myocardial infarction. Titers were arbi-
trarily classified as seronegative (8), intermedi-
ately positive (>8, 32), or highly positive (64).
Those who had serum antibodies that persisted 3
months later were treated with one or two
courses of azithromycin (500 mg per day orally
for 3 days). Treated patients had a fivefold
decrease in cardiovascular events and a
reduction in immunoglobulin (Ig)G titer (49).
The second study included 202 patients
hospitalized with unstable angina or non-Q wave
infarctions. The study was randomized with half
of the patients receiving roxithromycin (150 mg
twice a day for 30 days) and the other half
receiving a placebo. Serology was not considered
for inclusion or exclusion in the study. After 30
days, a statistically significant decrease in
cardiovascular events was observed in treated
patients, while those receiving the placebo were
treated only when a combined endpoint of severe
recurrent angina, acute myocardial infarction,
or ischemic death was used (50).
In the third (randomized) study, 88 patients
with percutaneous coronary revascularization
procedures were treated with azithromycin (500
mg per day for 2 days and 250 mg per day for 28
days) or received placebo (51). After 6 months,
patients receiving azithromycin had lower
frequencies of both angiographically confirmed
restenosis (9% versus 16%) and recurrent angina
(40%) than patients receiving placebo (60%). No
changes in antibody titers were observed after
azithromycin treatment. Despite study limita-
tions (52) and antiinflammatory effects of the
antibiotic on atherosclerosis, the results are
encouraging and warrant carefully designed
larger-scale intervention studies with longer
observation times.
Conclusions
A causative role of C. pneumoniae infection
in cardiovascular disease has not yet been firmly
established. However, the high frequency of
infection found in human atherosclerotic tissue
in comparison to normal tissue, the induction
and progression of atherosclerotic-like inflam-
matory changes in infected animal models of
atherosclerosis, and the early results from
antichlamydial intervention studies in hu-
mans are consistent with a causative role of
C. pneumoniae in the disease process.
Dr. Campbell is a professor, Department of
Pathobiology, School of Public Health and Community
Medicine, University of Washington. Her overall research
focus is on chlamydial pathogenesis with an emphasis
on Chlamydia pneumoniae infection.
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